Sporanox to be avoided in heart failure

The antifungal agent Sporanox (itraconazole) should not be used in patients with congestive heart failure or a history of congestive heart failure unless the benefit clearly outweighs the risk.

The warning follows observations that Sporanox exerts a negative inotropic effect, and reports of congestive heart failure associated with its use.

If the benefits do exceed the risk of using Sporanox in patients with heart failure, such patients should be monitored closely and the drug discontinued if symptoms of heart failure develop.

View Sporanox drug record

Further Information: Janssen-Cilag Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Two new steroid inhalers launched

Two new steroid inhalers launched

A new beclometasone metered-dose inhaler and a new...

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients prescribed statins fail to reach their...

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

The SGLT2 inhibitor dapagliflozin (Forxiga) can now...

Quick-reference MIMS COPD prescribing resources updated

Quick-reference MIMS COPD prescribing resources updated

Concise MIMS resources on COPD management and antibiotic...